Page 38 - Read Online

Page 14 of 15 Geerlings et al. Microbiome Res Rep 2024;3:36 https://dx.doi.org/10.20517/mrr.2024.06

Copyright
© The Author(s) 2024.

REFERENCES
1. de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut 2022;71:1020-32. DOI PubMed
PMC
2. Tims S, Derom C, Jonkers DM, et al. Microbiota conservation and BMI signatures in adult monozygotic twins. ISME J 2013;7:707-17.
DOI PubMed PMC
3. Le Chatelier E, Nielsen T, Qin J, et al; MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers.
Nature 2013;500:541-6. DOI PubMed
4. Allin KH, Tremaroli V, Caesar R, et al; IMI-DIRECT consortium. Aberrant intestinal microbiota in individuals with prediabetes.
Diabetologia 2018;61:810-20. DOI PubMed PMC
5. Zhong H, Ren H, Lu Y, et al. Distinct gut metagenomics and metaproteomics signatures in prediabetics and treatment-naïve type 2
diabetics. EBioMedicine 2019;47:373-83. DOI PubMed PMC
6. Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in
intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015;5:8096. DOI PubMed PMC
7. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64. DOI PubMed
8. Hanssen NMJ, de Vos WM, Nieuwdorp M. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a
bright future? Cell Metab 2021;33:1098-110. DOI PubMed
9. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021;19:55-71. DOI PubMed
10. Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Front Microbiol 2017;8:1765. DOI
PubMed PMC
11. Bui TPN, de Vos WM. Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases. Best Pract
Res Clin Endocrinol Metab 2021;35:101504. DOI PubMed
12. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading
bacterium. Int J Syst Evol Microbiol 2004;54:1469-76. DOI PubMed
13. Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: when, where, and
how? Microorganisms 2018;6:75. DOI PubMed PMC
14. Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Author Correction: Akkermansia muciniphila: paradigm for next-
generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol 2022;19:682. DOI PubMed
15. Belzer C, de Vos WM. Microbes inside - from diversity to function: the case of Akkermansia. ISME J 2012;6:1449-58. DOI PubMed
PMC
16. Dao MC, Everard A, Aron-Wisnewsky J, et al; MICRO-Obes Consortium. Akkermansia muciniphila and improved metabolic health
during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 2016;65:426-36. DOI PubMed
17. Karcher N, Nigro E, Punčochář M, et al. Genomic diversity and ecology of human-associated Akkermansia species in the gut
microbiome revealed by extensive metagenomic assembly. Genome Biol 2021;22:209. DOI PubMed PMC
18. Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced
obesity. Proc Natl Acad Sci U S A 2013;110:9066-71. DOI PubMed PMC
19. Wang F, Cai K, Xiao Q, He L, Xie L, Liu Z. Akkermansia muciniphila administration exacerbated the development of colitis-
associated colorectal cancer in mice. J Cancer 2022;13:124-33. DOI PubMed PMC
20. Qu S, Fan L, Qi Y, et al. Akkermansia muciniphila alleviates dextran sulfate sodium (DSS)-induced acute colitis by NLRP3 activation.
Microbiol Spectr 2021;9:e0073021. DOI PubMed PMC
21. Bian X, Wu W, Yang L, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative
colitis in mice. Front Microbiol 2019;10:2259. DOI PubMed PMC
22. Yaghoubfar R, Behrouzi A, Ashrafian F, et al. Modulation of serotonin signaling/metabolism by Akkermansia muciniphila and its
extracellular vesicles through the gut-brain axis in mice. Sci Rep 2020;10:22119. DOI PubMed PMC
23. Wu F, Guo X, Zhang M, et al. An Akkermansia muciniphila subtype alleviates high-fat diet-induced metabolic disorders and inhibits
the neurodegenerative process in mice. Anaerobe 2020;61:102138. DOI PubMed
24. Ottman N, Davids M, Suarez-Diez M, et al. Genome-scale model and omics analysis of metabolic capacities of Akkermansia
muciniphila reveal a preferential mucin-degrading Lifestyle. Appl Environ Microbiol 2017;83:e01014-17. DOI PubMed PMC
25. van der Ark KCH, Aalvink S, Suarez-Diez M, Schaap PJ, de Vos WM, Belzer C. Model-driven design of a minimal medium for
Akkermansia muciniphila confirms mucus adaptation. Microb Biotechnol 2018;11:476-85. DOI PubMed PMC
26. Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium
improves metabolism in obese and diabetic mice. Nat Med 2017;23:107-13. DOI PubMed
27. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers:
a proof-of-concept exploratory study. Nat Med 2019;25:1096-103. DOI PubMed PMC
28. van der Ark KCH. Metabolic characterization and viable delivery of Akkermansia muciniphila for its future application. 2018.
Available from: https://www.proquest.com/openview/d51699682401c1858ddc78c47dba7bfd/1?pq-origsite=gscholar&cbl=2026366&